AEZS Stock Summary and Trading Ideas (Aeterna Zentaris | NASDAQ:AEZS)

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

Aeterna Zentaris trades on the NASDAQ stock market under the symbol AEZS.

As of April 17, 2024, AEZS stock price climbed to $1.98 with 894 million shares trading.

AEZS has a beta of 0.52, meaning it tends to be less sensitive to market movements. AEZS has a correlation of 0.01 to the broad based SPY ETF.

AEZS has a market cap of $9.61 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AEZS stock traded as high as $29.25 and as low as $1.36.

AEZS has underperformed the market in the last year with a price return of -24.4% while the SPY ETF gained +23.0%. AEZS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.0% and -6.2%, respectively, while the SPY returned +5.7% and -3.5%, respectively.

AEZS support price is $1.86 and resistance is $2.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEZS stock will trade within this expected range on the day.